Nuclea has developed a number of pan antibodies that greatly simplify and accelerate the drug discovery processes in the MAPKAP Kinase (TK) disciplines. TK's are the most popular targets for new drug discovery in the oncology arena with significant advances in both genomics and proteomics. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers.
MAPKAP Kinases are serine/threonine kinases activated by phosphorylation by the SAPK2/3 (or p38) family of stress-activated kinases. MAPKAP Kinase 2 and 3 phosphorylate substrates ncluding CREB (Ser 133) and HSP27. MAPKAP kinases are similar to Rsk kinases (Rsk1, Rsk2, and Rsk3, also known as MAPKAP kinases 1a, 1b, and 1c), which are activated by mitogen-signaling pathways. Following activation, Rsk translocates to the nucleus; Rsk1 phosphorylates Ser133 of CREB, activating it as a transcription factor, while Rsk2 phosphorylates Ser10 of histone H3, a critical step in the stimulation of immediate-early gene expression.
•Is analogous to the Pan-Phosphoprotein (MAPKAP) antibody that recognizes any protein that is phosphorylated on the serine, threonine, or tyrosine residues.
•Can be used for both Immunoprecipitations and Western Blots.
•Of interest to any research lab working with Rsk receptors, Histone H3 or the aforementioned proteins will be interested in this antibody.
Starter Sets - 50ug
Antibody
Full Antibody-300ug
Antibody
Custom Aliquots
Please
Nuclea Biomarkers, LLC
105 South St.
Pittsfield, MA 01201
Phone: 413-749-4705
Fax: 413-445-9930
